You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

You are here

Aspirin Protects Heart Against Ischemia-reperfusion Injury Via LKB1-Sestrn2-AMPK Signaling Cascade

Authors

Yanping Bi MD, Shaoxin Lu MS3, Chelsea Luckett, Ji Li PhD, UNIV OF MISSISSIPPI MED CENTER, Jackson, MS

Introduction

AMP-activated protein kinase (AMPK) is a stress signaling enzyme that orchestrates the regulation of energy pathways. Intrinsic AMPK activation protects the heart against ischemic injury, but whether the pharmacologic AMPK stimulation by aspirin mitigates ischemia-reperfusion (I/R) damage is unknown.

Hypothesis

Aspirin as an emerging AMPK agonist could stimulate the cardiac AMPK signaling pathway that attenuates myocardial ischemia-reperfusion injury.

Methods

The cardioprotective activity of aspirin was evaluated in an in vivo regional I/R (45 min/24 hours) injury model in which the left anterior descending coronary artery (LAD) was occluded and released. The Langendroff perfused heart system was used to approach an ex vivo global ischemia and reperfusion model.

Results

Isolated mouse hearts ex vivo pre-treated with aspirin had better recovery of left ventricular contractile function (55% vs. 29% of baseline heart rate-pressure product; p<0.05) and less myocardial necrosis (56% reduction in infarct size; p<0.01) during post-ischemic reperfusion. Pre-treatment with aspirin in vivo attenuated myocardial infarction in C57BL/6J mice undergoing left coronary artery occlusion and reperfusion compared to vehicle (36% vs. 18%, p<0.05). Mouse hearts with genetically inactivated AMPK catalytic subunit were not protected by aspirin treatment, indicating the critical role of cardiac AMPK activation by aspirin in cardioprotection against ischemic injury. Moreover, pre-treatment with aspirin in vivo increased the AMPK downstream phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2), preserved energy charge during ischemia and delayed the development of ischemic contracture. Aspirin treatment augmented the interaction between AMPK upstream LKB1 and Sestrin2-AMPK complex, also enhanced activation of AMPK downstream endothelial nitric oxide synthase (eNOS) during ischemia, which partially attenuated myocardial stunning.

Conclusion

AMPK is a therapeutic target that can be stimulated by a direct-acting small molecule in order to prevent injury during I/R. The use of aspirin may represent a novel strategy to protect the heart and other solid organs against ischemia.

Back to the March 2019 issue of ACP IMpact